Docetaxel and capecitabine for advanced gastric cancer: investigating dose-dependent efficacy in two patient cohorts. - Wikidata - awgldk - TriplyDB

Docetaxel and capecitabine for advanced gastric cancer: investigating dose-dependent efficacy in two patient cohorts.

Docetaxel and capecitabine for advanced gastric cancer: investigating dose-dependent efficacy in two patient cohorts.

http://www.wikidata.org/entity/Q35208094

about

Capecitabine in gastric cancer.Bi-weekly docetaxel and 5-fluorouracil: an effective and feasible treatment for advanced gastric cancer with poor performance status.S-1-based chemotherapy versus capecitabine-based chemotherapy as first-line treatment for advanced gastric carcinoma: a meta-analysis.Second-Line Irinotecan, Leucovorin, and 5-Fluorouracil for Gastric Cancer Patients after Failed Docetaxel and S-1 Evaluation of chemosensitivity prediction using quantitative dose-response curve classification for highly advanced/relapsed gastric cancer.Phase II study of neo-adjuvant chemotherapy for locally advanced gastric cancer.Phase II study of docetaxel, cisplatin and capecitabine as preoperative chemotherapy in resectable gastric cancer.Capecitabine in the treatment of esophageal and gastric cancers.Capecitabine for the treatment of gastric cancer.Quality of life with biweekly docetaxel and capecitabine in advanced gastro-oesophageal cancer.Perioperative chemotherapy with docetaxel, cisplatin and capecitabine (DCX) in gastro-oesophageal adenocarcinoma: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO){dagger}.Response to preoperative chemotherapy predicts survival in patients undergoing hepatectomy for liver metastases from gastric and esophageal cancer.Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer.Dose-dense biweekly docetaxel combined with 5-fluorouracil as first-line treatment in advanced gastric cancer: a phase II trial.

P2860

Q34236005-9EB59B47-19EC-4464-86BC-B34178C0456E Q34447512-0618C8E5-4DB9-4EDF-9D7E-E8642CBD476F Q35070531-7130D44F-A51C-464A-A7CC-18FB4602F502 Q36453663-E07640F8-246D-4AC3-9E81-8DFE4F71B293 Q36581377-E212D13A-2B95-4CE7-8C82-22FA8DA0A766 Q37236380-13D5AECD-C6DD-4D17-A087-005AA26E742C Q37369163-2AD41409-B89D-4110-9A48-8FBB35E19F97 Q38148794-1ADE9760-F84F-4E60-9F09-7CE229523AAA Q38608072-7ABC3B24-2747-4471-BFB2-304D791F3522 Q40060365-4CF0DBD3-107F-4AB0-A40F-E8A117AD4F61 Q40282337-1392FA70-E284-4D68-B8D6-BCAD87900E96 Q46972090-58BA74E7-B19C-478E-98D5-A6E0D68A0970 Q47402625-0CC12873-F4B0-4B93-904E-C657E3983CB8 Q48052472-74BF7EA9-595A-4F09-88DF-DED256DE8BEF

P2860

Docetaxel and capecitabine for advanced gastric cancer: investigating dose-dependent efficacy in two patient cohorts.

http://www.wikidata.org/entity/Q35208094

description

2011 nî lūn-bûn

@nan

2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Docetaxel and capecitabine for ...... ficacy in two patient cohorts.

@ast

Docetaxel and capecitabine for ...... ficacy in two patient cohorts.

@en

type

label

Docetaxel and capecitabine for ...... ficacy in two patient cohorts.

@ast

Docetaxel and capecitabine for ...... ficacy in two patient cohorts.

@en

prefLabel

Docetaxel and capecitabine for ...... ficacy in two patient cohorts.

@ast

Docetaxel and capecitabine for ...... ficacy in two patient cohorts.

@en

P1433

Q35208094-BC4BAC43-3841-43EF-816D-86BEB01838C6

P1476

Q35208094-EA9C1E92-9E6C-49FA-9CEE-585EC4CAE29F

P2093

Q35208094-2C97E0D6-05A2-4CEA-9049-B0D56F8F5519

Q35208094-2F7948B3-8EEE-4428-A636-3005B917AEA3

Q35208094-79F3D51E-B1FC-4D10-AC82-D64FFEFA0BC9

Q35208094-85D41F0F-3856-46DB-B561-C335FF968F14

Q35208094-94ABDA1E-FB13-48E6-B212-E2A340B3A6F5

Q35208094-9DDB651B-4EB8-4D0D-BC98-AEF8A252E496

Q35208094-BA978582-05B9-4848-B8E1-FBF4B733FE3D

Q35208094-C7B63C4C-8AF0-46B2-A53A-94E54C9385DF

Q35208094-C90C054D-4F17-4015-B482-E10D73FCC2DD

Q35208094-EC804349-B772-46BF-B2D4-CD3896FD5DB1

P2860

Q35208094-1030AE03-40E1-4409-9256-07903DC7B8C0

Q35208094-1C14BA69-AA6D-474D-85F0-DCD39E064776

Q35208094-1DD297DD-613F-4206-8EFA-407BA2FE347A

Q35208094-1E88FA9C-0068-43BF-A7F6-A5E6FECCAD47

Q35208094-23A806D3-C133-4575-9D23-07AFCFE8F86B

Q35208094-2D60F207-3446-479E-BAD1-C8F9E0C06B1C

Q35208094-2F388B50-43AB-40A5-B2EA-45C522E88A6E

Q35208094-38B24B87-C69B-4F9A-AD22-5D51131AEFF6

Q35208094-439AEC86-20E3-429A-97C9-3840469D411A

Q35208094-47F7C71D-C6D6-4575-AE58-32D13BCAC6B6

P2888

Q35208094-42B76AE8-9A62-46C9-BD2D-B9493A40E027

P304

Q35208094-9A125F5E-33C8-48E8-85B8-D8B60A3FAAAF

P31

Q35208094-15D4ADBE-16A9-449A-AFDD-37D8C69A4C57

P356

Q35208094-E4B748C7-6202-4A3E-8382-E511AA0E216B

P407

Q35208094-B93CDBC2-B250-4C0A-B149-E5B9A94893D7

P433

Q35208094-4EA8131C-4822-4E55-8063-A511ABDC518B

P478

Q35208094-2B203442-784D-438A-BECC-3EE694822EC6

P577

Q35208094-E08948F1-654C-4FF3-9CE3-492AC12D2212

P5875

Q35208094-F6C281B5-884D-4295-8DD2-241E794A2AB7

P698

Q35208094-C4E917F8-622A-4D6F-931F-44E0233F8E76

P921

Q35208094-C69135DC-B864-4AB2-90A7-41E68FEA395B

P932

Q35208094-A41AEB9A-49C8-440A-9EBF-D7F93DC87EEE

P356

P1433

British Journal of Cancer

P1476

Docetaxel and capecitabine for ...... ficacy in two patient cohorts.

@en

P2093

A Kretzschmar

http://www.w3.org/2001/XMLSchema#string

C Grieser

http://www.w3.org/2001/XMLSchema#string

D Bichev

http://www.w3.org/2001/XMLSchema#string

F Rothmann

http://www.w3.org/2001/XMLSchema#string

I Blau

http://www.w3.org/2001/XMLSchema#string

I Schwaner

http://www.w3.org/2001/XMLSchema#string

K Breithaupt

http://www.w3.org/2001/XMLSchema#string

M Grothoff

http://www.w3.org/2001/XMLSchema#string

P C Thuss-Patience

http://www.w3.org/2001/XMLSchema#string

P Reichardt

http://www.w3.org/2001/XMLSchema#string

P2860

Chemotherapy for advanced gastric cancer

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world

Phase II study of low-dose docetaxel/fluorouracil/cisplatin in metastatic gastric carcinoma.

Capecitabine and oxaliplatin for advanced esophagogastric cancer.

Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer.

The impact of primary tumour origins in patients with advanced oesophageal, oesophago-gastric junction and gastric adenocarcinoma--individual patient data from 1775 patients in four randomised controlled trials.

Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial.

Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.

Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.

P2888

P304

505-512

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/BJC.2011.278

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

105

http://www.w3.org/2001/XMLSchema#string

P577

2011-07-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51523948

http://www.w3.org/2001/XMLSchema#string

P698

21792201

http://www.w3.org/2001/XMLSchema#string

P921

P932

3170974

http://www.w3.org/2001/XMLSchema#string